Mounjaro 5mg next day delivery

Mounjaro 5mg next day delivery

£150.00

Mounjaro 5mg next day delivery

Mounjaro 5 mg is a prescription medication that contains tirzepatide, a novel glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. It is approved for the treatment of type 2 diabetes mellitus and is being investigated for use in weight management.

This description is for educational purposes only. Mounjaro can only be prescribed by a licensed healthcare professional and is not available without a prescription.

What is Mounjaro 5 mg?

  • Active ingredient: Tirzepatide

  • Strength: 5 mg per injection

  • Formulation: Prefilled, single-dose injection pen for subcutaneous use

  • Drug class: Dual GIP and GLP-1 receptor agonist

The 5 mg dose is an intermediate step in treatment, usually after starting at 2.5 mg.

How Mounjaro Works

Tirzepatide is the first medication to target both GIP and GLP-1 receptors. It works by:

  • Enhancing insulin secretion when blood sugar is high

  • Suppressing glucagon (a hormone that raises blood sugar)

  • Slowing gastric emptying and reducing appetite

  • Supporting sustained blood sugar control and weight reduction

Clinical Uses

  • Primary indication: Improving glycemic control in adults with type 2 diabetes mellitus, as an adjunct to diet and exercise.

  • Emerging use: Clinical trials show promising results for weight management in people with obesity or overweight, though regulatory approvals may differ by country.

Dosage and Administration (educational summary)

  • Treatment is usually initiated at 2.5 mg once weekly.

  • After 4 weeks, the dose may be increased to 5 mg once weekly, depending on patient response and tolerance.

  • The dose may be further titrated in 2.5 mg increments up to 15 mg once weekly.

  • Administered by subcutaneous injection in the abdomen, thigh, or upper arm.

Side Effects

Common side effects:

  • Nausea

  • Vomiting

  • Diarrhea

  • Constipation

  • Decreased appetite

Serious but less common risks:

  • Pancreatitis (severe abdominal pain, nausea, vomiting)

  • Gallbladder disease

  • Hypoglycemia (especially if combined with insulin or sulfonylureas)

  • Rare allergic reactions

Safety Considerations

  • Boxed warning: Animal studies have shown a risk of thyroid C-cell tumors. Not recommended for individuals with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2).

  • Use with caution in people with severe gastrointestinal disease.

  • Not approved for type 1 diabetes or for use in children.

Patient Counseling Points

  • Inject once weekly, on the same day each week.

  • Can be taken with or without food.

  • If a dose is missed, it can be given within 4 days; otherwise, skip and take the next scheduled dose.

  • Store pens in the refrigerator until ready for use.

  • Report any severe abdominal pain or persistent nausea/vomiting to a healthcare provider immediately.

Regulatory Note (UK & global context)

    • In the UK and most regions, Mounjaro is classified as a prescription-only medicine (POM).

    • It should only be prescribed by a licensed healthcare professional as part of a structured diabetes management or weight-management program.